Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data
Our study found no clear difference between etanercept and infliximab biosimilars and their bio-originators for infection incidence, suggesting a similar safety profile.
Authors
- Waqqas Afif (ORCID: https://orcid.org/0000-0001-6869-0982)
- Gilles Boire (ORCID: https://orcid.org/0000-0003-2481-5821)
- Marina Gabriela Birck (ORCID: https://orcid.org/0000-0003-3003-1839)
- Sasha Bernatsky (ORCID: https://orcid.org/0000-0002-9515-2802)
- Harminder Singh (ORCID: https://orcid.org/0000-0002-9354-2356)
- D. Choquette (ORCID: https://orcid.org/0000-0001-6585-7695)
- Walter P. Maksymowych (ORCID: https://orcid.org/0000-0002-1291-1755)
- Luck Lukusa
Institutions
- Université de Sherbrooke (CA)
- University of Alberta (CA)
- McGill University Health Centre (CA)
- Centre Hospitalier Universitaire de Sherbrooke (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- University of Manitoba (CA)
- McGill University (CA)
Publication Details
- Journal
- BMC Rheumatology
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s41927-024-00415-5
- Citations
- 1
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.24
Funders
- Canadian Institutes of Health Research